Novo Nordisk Stock Plunges After Trial for New Weight Loss Drug ...

Dec 20, 2024 · Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's ...

CouponFollow Extension

20%
OFF

Novo Nordisk Shares Plunge 20% After Disappointing Trial Results; …

4 weeks from now

Dec 20, 2024 · Shares of Novo Nordisk plummeted roughly 20% on Friday. The fall comes after the Danish pharmaceutical giant reported results in a late-stage trial for its experimental …

nbcchicago.com

20%
OFF

Novo Nordisk Plunges 20% After Weight-Loss Drug Trial Misses …

4 weeks from now

Dec 20, 2024 · Novo Nordisk (NYSE:NVO), the titan of weight-loss treatments and maker of Wegovy and Ozempic, took a brutal hit on Friday. The company's shares nosedived 29%one …

yahoo.com

18%
OFF

Novo Nordisk Stock Plunges After Disappointing Obesity Drug Data

4 weeks from now

Dec 20, 2024 · Shares of the pharmaceutical giant fell 18% after a late-stage weight-loss drug trial missed ... Novo Nordisk Stock Plunges After Disappointing Obesity Drug Data ... 40 New 4 …

morningstar.com

18%
OFF

Novo Nordisk Stock Crashes 18% After New Obesity Drug Misses …

4 weeks from now

Dec 20, 2024 · That topped the 16.1% loss for patients who took semaglutide, the active ingredient behind Novo's weight-loss blockbuster Wegovy and diabetes drug Ozempic. But it …

investors.com

19%
OFF

Novo Nordisk Sinks On Disappointing Trial Results For Next Gen …

4 weeks from now

Dec 20, 2024 · Novo Nordisk's U.S.-listed shares tumbled over 19% Friday morning after it released data from a new weight loss drug trial. The new drug, CagriSema, led patients to lose …

investopedia.com

20%
OFF

EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk …

4 weeks from now

Dec 20, 2024 · Novo Nordisk's stock plunges 20% after underwhelming weight-loss trial results for its obesity drug. Analysts say market overreacted.

benzinga.com

20%
OFF

Novo Nordisk Stock Plunges After Disappointing... | Morningstar

4 weeks from now

Dec 20, 2024 · Novo Nordisk Stock Plunges After Disappointing Obesity Drug Data Shares of the pharmaceutical giant plummeted 20% after a late-stage weight loss drug trial missed …

morningstar.co.uk

$100
OFF

Novo Nordisk Shares Plunge After New Obesity Shot Disappoints

4 weeks from now

Novo Nordisk ’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out nearly $100 billion of the drugmaker’s stock-market value.

wsj.com

$125
OFF

Novo Nordisk Shares Plummet After Weight-loss Drug’s ... - MSN

4 weeks from now

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value. …

msn.com

7%
OFF

Novo Nordisk's Hybrid Weight Loss Drug Falls Short On

4 weeks from now

Dec 20, 2024 · CagriSema achieved a 22.7% weight loss in REDEFINE 1 trial after 68 weeks, outperforming placebo and individual components. 40.4% of CagriSema users lost 25%+ body …

benzinga.com

5%
OFF

Novo Nordisk Stock Dives — And Corbus Crashes — After New …

4 weeks from now

Sep 20, 2024 · Novo Nordisk stock tumbled 5.5%, closing at 127.51. Shares of Corbus, which is working on a similar weight-loss drug, crashed 62.3% to 19.51. Meanwhile, shares of …

investors.com

25%
OFF

Novo Nordisk Shares Plunge After New Obesity Shot Falls Short Of ...

4 weeks from now

Dec 20, 2024 · The outcome falls short of the 25% weight loss Novo Nordisk had expected and dents its chances of becoming the company's next blockbuster drug after Ozempic and Wegovy.

morningstar.com

FAQs about Novo Nordisk Stock Plunges After Trial for New Weight Loss Drug ... Coupon?

Why did Novo Nordisk stock plunge?

(Photo: Reuters/Tom Little) COPENHAGEN: Shares in Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, plunged on Friday (Dec 20) after it announced disappointing results of a new drug study. ...

Why did Novo Nordisk stock tank?

Novo Nordisk's stock tanked after a highly anticipated drug trial disappointed. The study showed its new obesity drug helped people lose less weight than expected. Eli Lilly, a competitor in the market for GLP-1 weight loss drugs, was up about 5%. ...

Why did Novo Nordisk stock fall 21%?

Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's stock plunged 21% to trade at $82.03 per share shortly after the opening bell on Friday morning, hitting its lowest level in over a year. ...

Does Novo Nordisk's new weight-loss drug work better than current GLP-1 drugs?

Photo: Scanpix Denmark/AFP via Getty Images The U.S.-listed shares of Novo Nordisk A.S. were plunging toward their worst day in decades on Friday after the results from a late-stage trial showed that the Danish company’s new weight-loss drug works better than current GLP-1 drugs — but not as well as expected. ...

Why did Novo Nordisk's shares tumble 19% Friday morning?

Novo Nordisk's U.S.-listed shares tumbled over 19% Friday morning after it released data from a new weight loss drug trial. The new drug, CagriSema, led patients to lose 22.7% of their body weight on average, below the company's reported goal of 25%, per Bloomberg. ...

Why did Novo Nordisk stock dive?

Novo Nordisk’s stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares. Photo: Scanpix Denmark/AFP via Getty Images ...